New Approaches To Arthritis & Pain Control In Dogs & Cats – Zoetis Nexvet Anti Nerve Growth Factor (NGF) Monoclonal Antibody Injection
Ron Hines DVM PhD
In March of 2020, the FDA agreed to consider Pfizer’s tanezumab, the human form anti-nerve-growth factor (NGF), as a treatment for arthritis pain in people. Zoetis/Nexvet’s similar monoclonal antibody medications, ranevetmab and frunevetmab – one adapted for dogs (NV-01) and the other for cats (NV-02) (read here) were still in the developmental stages in late 2019. However, Zoetis, the current manufacturer, began promoting the product to veterinarians through webinars presented in September 2020.
Your veterinarians has the same tools today that your physician has to treat arthritic and other chronic pain:
1) We can give your dog NSAIDs like carprofen (Rimadyl®), firocoxib (Previcox®) or meloxicam (Metacam®) to decrease the joint inflammation that grinding joint surfaces produce and that lessen pain sensations in your dog’s brain as well. Cats have fewer options because they do not tolerate the long term use of those medications.
3) Some vets dispense narcotics like tramadol or fentanyl (Duragesic®) patches which are powerful blockers of all types of pain. Others hope that gabapentin (Neurontin®) will provide sufficient pain relief for your pet. Other than fentanyl, we really do not know how effective these medications are. (read here)
Unfortunately all three options have some drawbacks. As I mentioned, cats do not tolerate normal doses of NSAIDs for more than a day or two. Perhaps cats can tolerate these medications longer when the dose is very low. (read here) Not every dog can tolerate NSAIDs either. In some dogs these drugs produce erosions (ulcers) of the stomach and intestine. (read here) NSAIDs can occasionally cause kidney and liver issues as well. (read here)
Corticosteroids are very effective at decreasing the joint inflammation that arthritic dogs and cats suffer too. Their initial beneficial effects are very dramatic. But they have a host of very serious potential side effects when given long term that include, diabetes, weight gain, adrenal gland suppression, fluid retention, and increased susceptibility to infection.
Narcotics like fentanyl patches (Duragesic®) are very effective in blocking pain sensations in the brain. But with time, the dose that has to be given to obtain relief must be higher and higher. Also, because of diversion fears their long-term veterinary use is also frowned upon by the DEA.
There are a number of veterinarians who suggest acupuncture, homeopathic remedies and “alternative medicine” for pain control in your cat or dog. But there is really no evidence that any of these things actually work in pets or humans. ( read here & here ) Others suggest therapeutic laser therapy as an alternative to traditional physiotherapy and still others, drugs like amitriptyline and imipramine based on their use in human fibromyalgia. None of these procedures and medications are likely to do your pet harm. I personally do not believe that any of them are more helpful than giving your pet extra love and attention, but there is no harm done in trying them.
What Is Nerve Growth Factor (NGF) And How Does It Relate To My Pet’s Pain?
Nerve growth factor is a small, protein-like molecule that individual nerve cells (neurons) use to communicate with each other. In 1956, it was identified as a critical messenger in how nervous system connections (“its wiring circuits”) organize during development. NGF helps determine which neurons survive and prosper ( read here ) and has more recently been found to have a host of different functions within the mature body ranging from insulin secretion from the pancreas ( read here ) to allergic inflammation. ( read here )
The nerve highway through which signals travel in you and your pet is a two way street – somewhat like a tree and its branches. Some impulses/signals travel from the brain to the far ends of its branches throughout the body to tell cells there what to do. Others travel in the other direction, from the fine ends of its branches throughout the body to the brain. Those that go in that second direction tells the brain what is going on in those distant locations. Those incoming messages can tell you if that distant location is hot or cold, its position in relation to the rest of the body, its taste, its feel, its smell. Another message those nerves can send to the brain is pain in that distant area.
By 2006, it was known that blocking the effects of NGF blocked pain. ( read here ) By 2010 pharmaceutical companies were making use of that new knowledge in attempts to formulate medications which would block pain. ( read here) The Pfizer and Lilly drug companies alone invested $550 million dollars in their research on Tanezumab ; anticipating that successful human NGF-blocking medications would be a $1.23 billion dollar market. All the drugs that were contemplated were monoclonal antibodies (mAb’s) – sort of “smart bombs” that seek out and disable key transformation points in complex cellular processes. They are very complicated products – expensive to produce and expensive to test. They are all large complex molecules (large molecule drugs=biologics), as opposed to the “small molecule” medicines of the past.Galliprant® and other NSAIDs are “small molecule” medications). Today’s mAbs are generally developed initially in rodents. Then the product antibody molecule must be “humanized” so that the human body’s immune system does not recognize it as a foreign protein and destroy it. Once done, these drugs cannot be used in dogs or cats because the immune system of either species will recognize that its “humanized” molecule that does not belong in their bodies. The pet will then produce antibodies that destroy it. Needless to say, few veterinary pharmaceutical companies had the resources to modify these complex medications so that the immune systems of dogs and cats will accept them. The only veterinary mAb on the market so far is Zoetis’ Cytopoint® for itch relief in dogs.
What Can you Tell Me About The Company, Nexvet?
Fast forward to 2010. An Australian startup company, Nexvet, incorporates in Melbourne. It raises $31.5 million dollars from American venture capitalists based on its patented method to rapidly “peticize” monoclonal antibody drugs originally developed for humans so that the drugs can be used in dogs and cats. The pesky portion of the drug that was initially recognized as rodent is now recognized as dog or cat. The portion of the drug that actually neutralizes a target within the body remains unchanged. This innovation allows monoclonal antibody drugs created for humans to be quickly and economically adapted for use in dogs and cats. In 2014, corporate headquarters move to Dublin, Ireland. In April of, 2017 Zoetis purchases Nexvet for $85 million dollars. Zoetis is the owner of the, now patent-expired, Rimadyl® and the Trocoxil® dog arthritis patent and they saw it as “a good fit”. As with all modern start-ups, Nexvet operated at a loss since they had no approved products for sale. Their announcements and publications tend to be glowing to encourage the steady inflow of the capital they need to stay in business and pay salaries until – hopefully – their products came onto the market and proved their worth.
Does The FDA Require Veterinary Drugs To Undergo The Same Rigorous Clinical Studies That Human Drugs Require Before They Are Allowed To Be Sold?
It used to be that approved veterinary drugs became available ~ 8-10 years after the FDA allowed their human use. Drug patents last 20 years, but traditionally it took up to 10 years to get FDA approval and the patent clock began ticking when the patent was issued. Most often, veterinarians began using them after the patent had expired and their cost in generic form had dropped. That is changing. Actually some of these mAbs might be coming out for vet use before they are available for human use. The FDA is often satisfied with 6-12 month studies in dogs and cats, vs a 38 month larger study costing much much more in humans. Or, the FDA can be induced to approve a veterinary drug’s short-term use although the drug companies know that vets and owners will be using it longer term if it proves effective. Shorter studies can be valid for dogs and cats because their lives are shorter and side effects often appear earlier. Also, FDA apparently does not feel that liability issues are as much a concern when it is a dog or a cat, and not a person, that does poorly. It is also a convenient way for drug companies get low cost feedback applicable to the human counterpart drugs they are developing. Those released high-tech veterinary products can be quite expensive – like Cytopoint®. But segments of the American and European pet-owning public now have the disposable income to purchase these high-cost, state-of-the-arts medications. Others are so attached to their pets that they will mortgage the farm or their soul to buy them.
The Dog, Cat and Rat Studies – What Do They Tell Us?
To precisely study pain and pain control in animals, you have to inflict pain in this case, to an unlucky rat. When a cartilage-destroying chemical was injected into its right knee, the pain of the induced arthritis was blocked by the injection of an anti-nerve growth factor antibody given a few days after. Given later, it was less effective. It did not appear to the authors that blocking NGF caused any improvement in the inflamed joint- it just blocked the pain. A second team had a crack at it and their results were similar.
In 2014, a paid consultant for Nexvet, the Nexvet ’s Chief Scientific Officer and a third veterinarian published an article on the dog formulation of NGF blocker that Nexvet has in development. They concluded, based on questioning the 9 dog owners, that the dog’s pain level decreased after the injection (Better general activity, enjoyment of life, rising to stand, walking, running and climbing ). They acknowledged that there was no control group of dogs that received no medication and no placebo group which got dummy injections nor was there a group that received a dog NSAID currently on the market to see if there product produced greater relief. But in a previous study, one of the same authors reported that the effect of the dog anti-NGF was similar to the relief obtained with daily oral meloxicam, an NSAID.
In 2015, Nexvet funded another study in dogs in North Carolina. Twelve dogs were given the Nexvet dog product and 13 similar dogs were not. By the end of their 28-day study, there were “no changes detected within groups over time for either total pain score or index joint pain score” between the groups and “there were no statistical differences between the groups at any time point for absolute scores, or change in scores”. Their conclusions on effectiveness are based primarily on statistical P values. And for them to have much meaning, the dog numbers would have had to been considerably larger. It would also have been nice if they had compared their mAb drug’s effect to a group given NSAIDs like Rimadyl® or meloxicam. But that’s not to say that the drug was not effective – you just can’t really tell from the data submitted.
Nexvet publicized another in-house study in cats in 2016. They took 30 laboratory-bred cats, gave half the cats “felinized” anti-NGF (frunevetmab) and half only a saline injection. Four days later they injected an irritant into all the cat’s right hind paw. Over the next 7 days, the cats that had received the “felinized” anti-NGF injection appeared to recover from the foot pad pain faster than the ones that did not. Nexvet also made their cat anti-NGF available to 15 veterinary centers in the USA in 2015/2016 and presented their findings at a large veterinary conference. They reported that their drug seemed to help lame cats. But they noted that, like herding cats, judging if they were in pain was a very difficult thing to do and that the current client questionnaires left much to be desired. If frunevetmab is approved, they contemplate making it available to cat owners through their veterinarians as a monthly subcutaneous injection.
Here and there in their promotional literature, Nexvet states that 92% of cats have arthritic joint changes and so, are good candidates for pain control treatment. They refer back to a 2010 study. That study reviewed the x-rays of 100 cats of all ages. I personally believe that it is highly unlikely that x-rays are a valid assessment tool for arthritic or chronic musculoskeletal pain in cats. It most certainly is not in humans.
Only 50% of people over the age of 65 that have x-ray evidence of arthritic knee joint changes experience any pain. And those that have joint pain do not necessarily have x-ray evidence of arthritis. As for hip pain, only 9.1-15.6% of people experiencing it have any x-ray evidence of hip arthritis. Of those that did have evidence of hip arthritis, only 20% reported frequent hip pain. The same general finding apply to spinal arthritic pain. Cats and dogs can’t talk; but if they could I believe they would tell you the same thing.
There are a few other NGF studies in dogs and cats. But none of them tell us much about long-term effectiveness of these anti-NGF products – that is chiefly because no one has devised an accurate, non-subjective way to directly measure pain in out pets. 3-axis accelerometers aka activity monitors may be one solution. The studies do however indicate that short-term use of the two NGF inhibitors appears safe.
Those dog and cat studies all had flaws. They tell me very little regarding the true value of these medications. Pet owners and vets like myself are likely to be optimistic and hopeful – we tend to tilt toward the perception of improvement when we administer products – no matter what they are. The high placebo (sugar pill) effect seen in all of the Company-sponsored dog and cat studies attest to that. Most likely, it will only be when these Nexvet products are in general use that pet owners and veterinarians alike will come to know how effective they really are. I do hope they are a better option for your pet than NSAIDs – but at this time, nobody can tell you that for sure.
Reluctance To Move Is Not The Same Thing As Pain
There are a host of non-arthritic issues that these client check lists-based studies could confuse with pain. Overweight dogs and cats are likely to be sluggish. Pets with age or nutritionally-related sarcopenia (muscle wasting) won’t get about as well as they once did. Vision problems create hesitancy. So does mental decline (CDS) and metabolic imbalances such as hepatic encephalopathy. Heart, kidney, lung issues and anemia can be underlying causes of weakness and immobility as well. Shy dogs and cats are likely to be hesitant. No part of your dog or cat’s body is immune to the effects of aging. The older you pet is, the more likely it is that it is facing a mixed group of health issues that is slowing it down – pain may or may not be one of them.
Are You Dodging The Question, Are These Drugs Likely To Help My Dog Or Cat Or Not?
As I said, I hope they will, but I cannot tell you that with certainty – yet.
The basic science behind them appears valid and it would be great if both of Nexvet ‘s cat and dog NGF-blocking drugs were unqualified successes. Goodness knows our pets could use better pain control options than veterinarian like me have to offer you today. But its impossible to evaluate these two products intelligently from the data that is out there because of the ways the studies were purposely set up. All the publications were underwritten by Nexvet. When a company has a product to sell and wants to interest you in buying it, exaggeration and a tilt to favorability can be assumed. Would Ford suggest you to buy a Chevy ? When one does a truck comparison test commercial, do your think their product will come in last ? It has also become harder and harder for me and others to judge the true worth of scientific publications across all fields of medicine.
What keeps me most positive and hopeful is that Zoetis – an offshoot of Pfizer – was willing to pay $85 million dollars for Nexvet as well as this class of drug’s apparent effectiveness in rodents. But I do not know if Zoetis bought Nexvet to control its “petification” process – one that will have a multitude of other uses because of the potential of these two medications to eliminate a potential competitor or some combination of the above.
Pfizer itself is well on its way to marketing its own human NGF blocker, tanezumab. There were some concerns that suppressing pain receptors with their NGF inhibitor might suppress or alter other portions of the nervous system (the sympathetic nervous system). But they seem to have been laid to rest. In June of 2017, Pfizer’s tanezumab ’s clinical trials were placed on FDA Fast Track approval/disapproval status for arthritis and lower back pain – partially due to their less addictive potential during our current opioid overdose crisis. If Pfizer’s tanezumab is a success, the Nexvet products probably will be too. FDA’s Pfizer human knee and hip clinical trials are set to complete by August 2, 2018; back pain by October 25, 2017.
Is Pain Always Bad?
It is always unpleasant, it is always unwanted, but it is not necessarily bad.
Acute and chronic pain are quite different. I worked for Dr. Norman Cornelius, the best race track veterinarian In Illinois. I was too young to enter the bleachers, but I worked the back stables dragging around his X-ray machine and holding the twitch. We dispensed a lot of “bute” in those days – the owners demanded it to get their lame horses back into the races as soon as possible. Dr. Cornelius was a wise man. He once told me as he was firing and bandaging a horses knee “you know, I could get this horse up and running again sooner with “bute”, but if I did, the trainer wouldn’t give the horse the rest it needs to heal. He had no faith in the firing and blistering processes; but he knew that the procedure and the bandages, were the only ways to placate the trainers and give their horse the time they needed to heal on their own. Back in 2015, Johnson & Johnson had their own fulranumab anti-NGF mAb in development to compete with Pfizer’s tanezumab. They began clinical trials of fulranumab for knee pain in in people in 2014. After paying 435 million dollars for the rights to the drug, J&J abruptly ended all tests during late-stage III human trials in 2016. They never revealed the reason why. But many observers noted that considerably more patients taking their mAb fulranumab drug injections in the J&J phase III trials needed artificial knee replacements before the study ended than those not receiving the drug. Similar issues led the FDA in October 2016 to halt clinical trials of Regeneron’s fasinumab – designed to test the drug for spinal arthritis, hip and knee pain. In Pfizer’s case, it appeared that the patients wore out their failing knees faster because the drug worked too well in relieving their knee pain. In Regeneron’s case it appeared that their mAb also accelerated joint arthritis (arthropathy) for the same reason. Not much different than those race track horses I knew long ago. ( read here ) So I suggest that your dog or cat not receive these type of mAb medications if there is any hope that time and rest will mend its problems. It is also still unclear if the Zoetis mAb product (its name has not yet been announced) is even as effective as what we have now to treat acute and long term pain in dogs. That is a different story when its your cat that is in pain. Veterinarians have very limited options to address felines pain at this time. That can go for all forms of pain killers when it comes to our pet’s ligamental tears, wounds and sprains. You want to give your dog and cat’s acute injuries a chance to heal. Rest and inactivity are a very important part of that. Put the Frisbee away for a while.
You are on the Vetspace animal health website